In short
A groundbreaking clinical trial is underway to investigate the potential of autologous muscle precursor cells, specifically mesoangioblasts, in treating mitochondrial myopathy caused by the m.3243A>G mutation. This innovative approach aims to improve muscle strength and function in patients with this rare genetic condition. The study focuses on the safety and effectiveness of intra-arterial administration of these cells to the upper arm, offering hope for those affected by this debilitating disorder.
At a glance
- Trial Name
- 2024-515129-27-00
- Condition
- Mitochondrial myopathy due to m.3243A>G mutation
- Treatment
- Intra-arterial autologous mesoangioblasts (muscle precursor cells)
- Primary Objective
- Assess effect and safety of three administrations to the biceps brachii muscle
- Key Measurements
- Muscle strength, fatigue, mass, morphology, mutation load, mitochondrial respiratory capacity
- Eligibility
- Adults 18-64 with heteroplasmic m.3243A>G mutation
- Safety Monitoring
- Angiography, neurological vital signs, adverse events
- Follow-up Period
- 4-6 weeks after third administration
What are Autologous Muscle Precursor Cells?
Autologous muscle precursor cells, also known as autologous mesoangioblasts or MABS06, are a type of cell therapy being studied for the treatment of certain muscle disorders. These cells are derived from the patient's own body, specifically from skeletal muscle tissue. The term "autologous" means that the cells come from the same individual who will receive the treatment, which can help reduce the risk of rejection by the immune system.
Target Condition: Mitochondrial Myopathy
The primary condition being targeted in this clinical trial is mitochondrial myopathy caused by a specific genetic mutation called m.3243A>G. Mitochondrial myopathy is a group of muscle diseases caused by damage to the mitochondria, which are the energy-producing structures in our cells. This condition can lead to muscle weakness, fatigue, and other symptoms that can significantly impact a person's quality of life.
How the Treatment Works
The treatment involves the following steps:
- Cells are collected from the patient's own muscle tissue.
- These cells are processed and grown in a laboratory to create a cell suspension for injection.
- The prepared cells are then administered back to the patient through intra-arterial injection. This means the cells are injected directly into an artery.
In this specific clinical trial, the treatment focuses on the biceps brachii (BB) muscle in the upper arm. Patients receive three separate injections of their own muscle precursor cells into the left arm.
Clinical Trial Objectives
The main goals of the clinical trial are:
- To assess the effect of the cell therapy on muscle strength and fatigue in the treated arm compared to the untreated arm.
- To evaluate the safety of the treatment, including monitoring for any serious side effects or complications.
- To measure changes in muscle mass, structure, and function before and after treatment.
Eligibility Criteria
To participate in this clinical trial, patients must meet certain criteria:
- Age: 18-64 years old
- Diagnosed with the m.3243A>G mutation causing mitochondrial myopathy
- Able to provide informed consent
There are also several factors that would exclude a person from participating, such as certain medical conditions, medications, or lifestyle factors. It's important to discuss these with a healthcare provider or the research team to determine eligibility.
Safety Considerations
The clinical trial places a strong emphasis on patient safety. Some key safety measures include:
- Monitoring for any serious adverse events (SAEs)
- Checking for potential vascular obstructions (blockages in blood vessels)
- Observing changes in neurological vital signs
- Performing angiography (a type of X-ray that looks at blood vessels)
- Close monitoring for 8 hours after each procedure
Potential Benefits
While the effectiveness of this treatment is still being studied, the researchers hope to see improvements in:
- Muscle strength and reduced fatigue in the treated arm
- Increased muscle mass
- Improved mitochondrial function in the treated muscle
- Reduced mutation load (the amount of abnormal mitochondrial DNA) in the treated muscle
It's important to note that this is an early-phase clinical trial (Phase I/II), which means that while the treatment shows promise, its full effects and long-term outcomes are still being investigated.